Home Reagents Clinical Chemistry Reagents Barbiturates assay
Quality Guranteed Fast Delivery ad for support

Barbiturates assay

Product Method Size Catalog Price Quantity
Barbiturates assay Homogenous EIA R1 2 x 16.9ml , R2 2 x 8ml DA4008 $647.20
Shipping costs will be added at the checkout stage, click here for charges.
  • Format
    Liquid ready to use
  • Assay Range
    _
  • Working Stability 15-25 °C
    _
  • Working Stability 2-8 °C
    28 days
Request Kit Insert

Intended Use

The Barbiturates assay is an in vitro diagnostic reagent. For the qualitative and semi-quantitative analysis of Barbiturates in human urine. The cut-off for the qualitative application is 200ng/ml. This product is suitable for use on the RX Series instruments, which includes the Rx Daytona and the Rx Imola.

This assay provides only a preliminary result. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result. To obtain a confirmed analytical result, a more specific alternate chemical method is needed. Gas chromatography/mass spectroscopy (GC/MS) is the recommended confirmatory method.


Clinical Significance

Barbiturates are a class of around 12 compounds derivatized from barbituric acid. They are central nervous system (CNS) depressants often used therapeutically as sedatives, hypnotics, anesthetics and anti-epileptic drugs.

It is because of the barbiturate’s sedative-hypnotic properties that they are frequently abused. Barbiturates are almost always taken orally as capsules or tablets and the effects resemble those of intoxication with alcohol. Chronic use of Barbiturates leads to tolerance and physical dependence, short acting Barbiturates taken at 400 mg/day for 2-3 months produces a clinically significant degree of physical dependence. Withdrawal symptoms experienced during periods of drug abstinence can be severe enough to cause death.

The short-acting barbiturates are extensively metabolized by the liver to more pharmacologically inactive hydroxylated compounds. Only a small amount (less than 5%) of the parent compound is excreted unaltered in the urine. The detection period for Barbiturates in the urine is 4-7 days.


Principle

The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity.

In the absence of drug in the sample, barbiturates-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. However, when free drug is present in the sample, antibody would bind to free drug; the unbound barbiturates-labeled G6PDH then exhibits its maximal enzyme activity.

Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at 340 nm.


Available Applications

  • Various